The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand for novel therapies across oncology, immunology, and cardiovascular health. With projections calling for the global biopharmaceuticals market to grow at a stable 8.5% compound annual growth rate (CAGR) spanning 2024 to 2032, one company that might be well-poised to benefit is Bristol-Myers Squibb Company (BMY).
BMY spiked 10.5% today on the heels of poorly received trial data for a schizophrenia treatment from its rival AbbVie (ABBV), which could bode well for the previously approved drug from Bristol-Myers. Adding to its appeal, Bristol Myers not only leads in cutting-edge therapies but also offers a highly attractive dividend yield, making it a standout choice for income-seeking investors.
